DREAMM 6
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- NCT03544281 ↗
- Completed
- GlaxoSmithKline
- Standard
We haven't built an HCP commentary report on DREAMM 6 (belantamab mafodotin plus lenalidomide plus dexamethasone; belantamab mafodotin plus bortezomib plus dexamethasone in relapsed/refractory multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DREAMM 6 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 11 | |
| YouTube | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin; Lenalidomide; Dexamethasone; Bortezomib
- Arms
- Arm A: Belantamab mafodotin+lenalidomide +dexamethasone · Experimental
- Arm B: Belantamab mafodotin+bortezomib+dexamethasone · Experimental
- Enrollment
- 153
- Primary outcomes
- Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A
- Number of Participants With DLTs, Treatment B
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF)
- Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
- Number of Participants With Worst-case Change Post-baseline in Hematology Parameters
- Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
- Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters
- Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein
- Change From Baseline in Urine Potential of Hydrogen (pH)
- Change From Baseline in Urine Specific Gravity
- Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
- Change From Baseline in Vital Signs : Pulse Rate
- Change From Baseline in Vital Signs : Temperature
- Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM)
- Sponsor
- GlaxoSmithKline with IQVIA Pty Ltd
- Start
- Sep 20, 2018
- Primary completion
- Feb 28, 2023
- Results posted
- Yes
- Registry record
- NCT03544281 · updated Mar 18, 2025